Patents by Inventor Linda S. Grais

Linda S. Grais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS OF L-ORNITHINE PHENYLACETATE
    Publication number: 20220202755
    Abstract: Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: June 30, 2022
    Inventors: Laurene Wang, Stanley Bukofzer, Linda S. Grais
  • Formulations of L-ornithine phenylacetate
    Patent number: 11219611
    Abstract: Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 11, 2022
    Assignee: Ocera Therapeutics, Inc.
    Inventors: Laurene Wang, Stanley Bukofzer, Linda S. Grais
  • FORMULATIONS OF L-ORNITHINE PHENYLACETATE
    Publication number: 20170135973
    Abstract: Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of L-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, hepatic encephalopathy, or patients with urea cycle disorders.
    Type: Application
    Filed: November 11, 2016
    Publication date: May 18, 2017
    Inventors: Laurene Wang, Stan Bukofzer, Linda S. Grais